At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed Apr 16, 2026 at 22:42 ET
Trevi Therapeutics priced an underwritten public offering of 11,600,000 shares at $13.00 per share, raising approximately $150 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 1,740,000 shares. The offering is expected to close on or about April 20, 2026, subject to customary conditions.
- Trevi Therapeutics is offering 11,600,000 shares of common stock at $13.00 per share.
- Total gross proceeds are approximately $150 million, before underwriting discounts and expenses.
- Underwriters have a 30-day option to purchase up to 1,740,000 additional shares.
- The offering is expected to close around April 20, 2026, subject to customary closing conditions.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access